Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02428855 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02428855: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02428855 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02428855, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This research study is studying Dasatinib as a possible treatment for cancer of bile ducts.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02428855
The ClinicalTrials.gov registry entry for NCT02428855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT02428855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02428855 about?
NCT02428855 is a clinical study titled "Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma". This research study is studying Dasatinib as a possible treatment for cancer of bile ducts.
What is the current status of trial NCT02428855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2015-04. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02428855?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT02428855?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.